WEBINAR: How to set yourself up for success with organ-on-a-chip

Available to watch on-demand now

cnb937 ooc success webinar promo bar v1 |
Watch webinar
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment

      • OBN Awards 2023 winner!

      • CN Bio appoints Neil Rumbelow as Director of Product Development

      View all news

      Upcoming Events

      Check back soon for upcoming events

      View all events

      Join the team!

      • Director of Sales – Americas Region

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Liver disease to become a bigger killer than heart disease or cancer

March 26, 2014

Liver disease has the potential to become the UK’s biggest killer within a generation, is the stark assessment of an independent report released today by a group of politicians and liver experts.

The damning report highlights the “scandalous” absence of a national strategy to tackle liver disease, the result of which is a “shameful waste of lives” and a growing burden on the UK’s National Health Service.

Amongst several recommendations put forward in the report, the UK’s Chief Medical Officer advocates prioritisation of actions towards the prevention, diagnosis and treatment of liver disease. But at a time when healthcare budgets are under considerable pressure the big question is “where will the money be found to finance such actions”?

Contributing to the challenge is the significant cost of new treatments for liver diseases. Sofosbuvir, a new hepatitis C drug, recently hit the market with an eye-watering $1,000 per day price tag. After a long and costly drug development process – typically taking more than 10 years and costing upwards of $1bn – companies like Gilead, the manufacturer of Sofosbuvir, have to hope that cost-benefit assessments made by governments and health insurers will work in their favour.

An alternative approach is for pharmaceutical companies to identify faster, more cost effective methods for developing drugs.  Thus reducing the time for patients to access life-changing treatments and providing such treatments at an affordable price.

CN Bio Innovations has developed several unique models of human liver disease which enable the rapid testing and development of new treatments, meaning that only the best drugs, are advanced into expensive and lengthy clinical trials. The company will be arranging meetings with interested parties  to  discuss details of its new liver disease models at one of the industry’s foremost conferences, The European Association for the Study of the Liver’s (EASL) International Liver Congress, which kicks off in London on April 9, 2014.

No doubt all of these topics – and more – will be the subject of hot debate at EASL!

Category iconBusiness

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment December 4, 2023
  • OBN Awards 2023 winner! November 23, 2023
  • CN Bio appoints Neil Rumbelow as Director of Product Development November 2, 2023

Upcoming events